MedTrace Logo

Obstructive Sleep Apnea (OSA), Hypertension , β1 Subunit of Maxi-k+ Channel and Cardiovascular Risk

NCT01791270 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2013-06-21

No results posted yet for this study

Summary

To describe the relationship between OSA and clinical Hypertension (performing ABPM), endothelial dysfunction (performing flowmetry), and its relation at the basic research (determining the β1 subunit in Peripheral Leukocytes in peripheral blood). This relation between OSA and HTA has been evaluated in basal conditions and after modifying the pathophysiological role of OSA applying treatment with positive continues pressure (CPAP) during 3 months.

Conditions

Interventions

DEVICE

Continuous positive airway pressure (CPAP) therapy

Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP. First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure). The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP. We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor. Procedures: 1. \- Respiratory Polygraphy 2. \- Ambulatory Blood Pressure Monitoring 3. \- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter. 4. \- ß1en subunit expression in peripheral blood leukocytes.

Sponsors & Collaborators

  • Junta de Andalucia

    collaborator OTHER_GOV

  • Angeles Sanchez Armengol

    lead OTHER

Principal Investigators

  • Angeles Sánchez Armengol, Md PhD · Hospitales Universitarios Virgen del Rocío

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-12-31
Completion
2012-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01791270 on ClinicalTrials.gov